Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

In conclusion, age does not impact the efficacy or safety of pembrolizumab in NSCLC, and therefore advanced age should not be a deterrent for treating these patients with pembrolizumab. Physicians and care providers can thus focus on other factors that may influence therapeutic outcomes.PMID:34677275 | PMC:PMC8534423 | DOI:10.3390/curroncol28050357

Source: Current Oncology - October 22, 2021 Category: Cancer & Oncology Authors: Heidi A I Grosjean Samantha Dolter Daniel E Meyers Philip Q Ding Igor Stukalin Siddhartha Goutam Shiying Kong Quincy Chu Daniel Y C Heng D Gwyn Bebb Don G Morris Winson Y Cheung Aliyah Pabani Source Type: research